Latest Articles

Publication Date
All News Scientific
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - The AI Journal

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer The AI Journal

Published: Oct. 18, 2025, 10:20 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational - GlobeNewswire

Genmab Announces New Data Demonstrating Investigational GlobeNewswire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - GlobeNewswire

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer GlobeNewswire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Yahoo Finance

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Yahoo Finance

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
The female scientists who finally found an answer to endometriosis wait times - The i Paper

The female scientists who finally found an answer to endometriosis wait times The i Paper

Published: Oct. 18, 2025, 5 a.m.
Read Full Article
Difficulties of screening dense breast tissue - Contemporary OB/GYN

Difficulties of screening dense breast tissue Contemporary OB/GYN

Published: Oct. 17, 2025, 7:40 p.m.
Read Full Article
Two Penn State faculty named fellows of the National Academy of Kinesiology - Penn State University

Two Penn State faculty named fellows of the National Academy of Kinesiology Penn State University

Published: Oct. 17, 2025, 3:07 p.m.
Read Full Article
Contemporary OB/GYN week in review: birth complications, fasting, and more - Contemporary OB/GYN

Contemporary OB/GYN week in review: birth complications, fasting, and more Contemporary OB/GYN

Published: Oct. 17, 2025, 1:05 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!